CK-1827452
Phase 2Small molecule
CK-1827452 is one of 34 small molecule programs targeting Ischemic Cardiomyopathy. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
CK-1827452
CCytokinetics
Phase 2
Xylocaine
MMEDRx USA, Inc.
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Neo-Synephrine
EExela Pharma Sciences, LLC.
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CK-1827452. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCytokinetics